2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 21:23, 15 November 2023
, 15 November 2023→Clinical Trials
| Line 233: | Line 233: | ||
*placebo, after 6 pm | *placebo, after 6 pm | ||
*250 mg, before 12 pm | *250 mg, before 12 pm | ||
* 250 mg, after 6 pm | *250 mg, after 6 pm | ||
| | | | ||
*108 older adults | *108 older adults | ||
| Line 239: | Line 239: | ||
| | | | ||
*NMN intake in the afternoon is more effective in improving lower limb function and reducing drowsiness in older adults. | *NMN intake in the afternoon is more effective in improving lower limb function and reducing drowsiness in older adults. | ||
|- | |||
|{{pmid_text|35182418}} | |||
|[[RCT]], 14 days | |||
*1 000 mg MIB-626 once daily | |||
*1 000 mg MIB-626 twice daily | |||
*placebo | |||
| | |||
*32 overweight or obese adults | |||
*55-80 years | |||
| | |||
*MIB-626 was well tolerated | |||
*Blood NMN concentrations significantly higher in treated groups compared to placebo | |||
*Substantial dose-related increases in blood NAD levels and its metabolome | |||
*Changes in NMN or NAD levels not related to sex, BMI, or age | |||
*Very little unmodified NMN excreted in urine | |||
*Facilitates design of efficacy trials in disease conditions | |||
|} | |} | ||